List of works - Andrea Sartore-Bianchi

A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits

scientific article published on 04 October 2019

A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

scientific article published on 12 December 2019

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

scientific article

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

scientific article published in December 2017

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

scientific article published on 8 December 2016

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

scientific article published on 6 November 2015

Acquired resistance to EGFR-targeted therapies in colorectal cancer

scientific article published on 14 May 2014

Adaptive mutability of colorectal cancers in response to targeted therapies

scientific article published on 07 November 2019

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

scientific article

Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer.

scientific article

Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?

scientific article published on July 2013

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

scientific article published on 09 October 2015

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

scientific article

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

scientific article published on 7 July 2015

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

scientific article published on 08 September 2009

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer

scientific article published in February 2014

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

scientific article

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions

scientific article published on 01 September 2020

Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer

scientific article published on 18 November 2019

Cetuximab for treatment of metastatic colorectal cancer

scientific article published on 01 June 2006

Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory

scientific article published on 6 May 2016

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer.

scientific article

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

scientific article

Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression

scientific article published on 25 February 2019

Detection of circulating tumor DNA in early- and late-stage human malignancies

scientific article (publication date: 19 February 2014)

Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.

scientific article published on 16 December 2016

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

scientific article published on 25 June 2015

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer

scientific article

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

scientific article

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.

scientific article published on 4 September 2017

EGFR FISH in colorectal cancer: what is the current reality?

scientific article

Early-onset colorectal cancer in young individuals

scientific article published on 22 December 2018

Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis

scientific article published on 25 January 2017

Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System

scientific article

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

scientific article

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

scientific article

Entrectinib for the treatment of metastatic NSCLC: safety and efficacy

scientific article published on 08 April 2020

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab

scientific article published on 01 August 2007

Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.

scientific article

Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ

scientific article published on 20 April 2021

Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

scholarly article published in Targeted oncology

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

scientific article published on 01 July 2015

Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study.

scientific article

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

scientific article published in May 2005

Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 function.

scientific article published on 22 July 2015

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer

scientific article published on 05 April 2019

Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer.

scientific article published on 19 October 2017

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

scientific article published on 29 November 2017

Increased incidence of colon cancer among individuals younger than 50 years: A 17 years analysis from the cancer registry of the municipality of Milan, Italy

scientific article published on 18 April 2019

Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

scientific article published on March 2010

Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?

scientific article published on 01 November 2002

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

scientific article

Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast

scientific article published on 30 June 2014

Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET)

scientific article published on 21 July 2017

Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab

scientific article

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

scientific article published on 03 July 2019

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

scientific article published on 16 June 2016

Molecular Markers Beyond Microsatellite Instability for Assessing Prognosis in Early-Stage Colorectal Cancer: What Happens at Relapse?

scientific article published on 01 April 2017

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

scientific article

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

scientific article published on 17 January 2017

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

scientific article published on 01 September 2008

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

scientific article

New frontiers in therapeutic resistance in cancer ⬇️

scientific article published on July 1, 2012

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

scientific article

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

scientific article

Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR.

scientific article published on 29 October 2016

Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study.

scientific article

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

scientific article

Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases ⬇️

scientific article published on July 18, 2013

Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer

scientific article published in November 2017

Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

scientific article published on 02 August 2019

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

scientific article published on 01 September 2020

Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer

scientific article (publication date: 2013)

Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

scientific article published on 26 February 2019

Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.

scientific article published on 6 April 2017

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience

scientific article

Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients

scientific article published on 01 April 2005

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

scientific article published on 19 August 2015

Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.

scientific article

Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer

scientific article published on 01 July 2018

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

scientific article

Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.

scientific article published on 24 January 2005

Rationale and clinical results of multi-target treatments in oncology

scientific article published on 01 January 2007

Regorafenib for metastatic colorectal cancer

Regorafenib in metastatic colorectal cancer.

scientific article

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.

scientific article

Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution

scientific article published on 07 October 2014

Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies

scientific article published on 27 December 2018

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

scientific article published on 9 February 2017

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

scientific article

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.

scientific article published on 10 January 2018

Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer

scientific article published on 12 July 2005

Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study.

scientific article published on 30 November 2011

TRKA expression and NTRK1 gene copy number across solid tumours.

scientific article

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.

scientific article

The Evolutionary Landscape of Treatment for <i>BRAF<sup>V600E</sup></i> Mutant Metastatic Colorectal Cancer

scientific article published on 04 January 2021

The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer

scientific article published on 01 September 2019

The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.

scientific article

The genomic landscape of response to EGFR blockade in colorectal cancer.

scientific article published on 30 September 2015

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

scientific article published on 30 April 2015

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.

scientific article

Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice

scientific article published on 16 November 2018

Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer

scientific article published on 01 October 2018

Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.

scientific article published on 24 March 2017

Translational challenges from the 2014 Gastrointestinal Cancers Symposium: toward a true tailored therapy through effective research

scientific article

Treatment sequencing in metastatic colorectal cancer

scientific article published on 25 January 2019

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

scientific article

Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer

scientific article published on 24 February 2016

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

scientific article

List of works by Andrea Sartore-Bianchi

A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits

A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

Acquired resistance to EGFR-targeted therapies in colorectal cancer

Adaptive mutability of colorectal cancers in response to targeted therapies

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer.

Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions

Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer

Cetuximab for treatment of metastatic colorectal cancer

Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression

Detection of circulating tumor DNA in early- and late-stage human malignancies

Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.

EGFR FISH in colorectal cancer: what is the current reality?

Early-onset colorectal cancer in young individuals

Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis

Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Entrectinib for the treatment of metastatic NSCLC: safety and efficacy

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab

Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.

Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ

Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study.

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 function.

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer

Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer.

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

Increased incidence of colon cancer among individuals younger than 50 years: A 17 years analysis from the cancer registry of the municipality of Milan, Italy

Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast

Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET)

Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

Molecular Markers Beyond Microsatellite Instability for Assessing Prognosis in Early-Stage Colorectal Cancer: What Happens at Relapse?

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

New frontiers in therapeutic resistance in cancer ⬇️

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR.

Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases ⬇️

Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer

Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer

Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience

Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.